Phase 3 N=216 Anidulafungin Candidemia/Invasive Candidiasis Intensive Care Study
Invasive Candidiasis
Primary: Percentage of Participants With Global Treatment Response Success at End of Treatment — 69.5 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=162 Invasive Candidiasis in Saudi ICUs
Invasive Candidiasis
Primary: Hospital Mortality — 95 Participants
Phase 4 N=222 Randomized Study of Caspofungin Prophylaxis Followed by Pre-emptive Therapy for Invasive Candidiasis in the Intensive Care Unit (ICU)
Invasive Candidiasis
Primary: Proven and Probable Invasive Candidiasis Based on Modified Mycoses Study Group/European Organization for Research and Treatment of Cancer (MSG/EORTC) Criteria. — 9.8…
Phase 3 N=450 Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections
Candidiasis, Invasive · Candidemia · Mycoses
Primary: Percentage of Participants With Overall Response of Success at the End of Intravenous Therapy (EOIV) as Determined by the Data Review Committee (DRC) Based on the…
Phase 3 N=204 A Multicenter, Randomized, Double-Blind, Comparative Study to Evaluate the Safety, Tolerability, and Efficacy of 2 Dosing Regimens of an Antifungal Drug in the Treatment of Fungal Infections in Adults (0991-801)(COMPLETED)
Invasive Candidiasis
Primary: Number of Patients Who Develop Significant Drug-related Adverse Events. — 2; 3 Participants
Phase 2 N=107 CD101 Compared to Caspofungin Followed by Oral Step Down in Subjects With Candidemia and/or Invasive Candidiasis-Bridging Extension
Candidemia · Mycoses · Fungal Infection
Primary: Incidence of Treatment Emergent Adverse Events [Safety and Tolerability] — 71; 49; 55 Participants
Phase 3 N=199 Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis
Candidemia · Mycoses · Fungal Infection
Primary: All-Cause Mortality (US FDA Only) — 19; 17; 3; 3 Participants
Phase 3 N=362 Fluconazole Prophylaxis for the Prevention of Candidiasis in Infants Less Than 750 Grams Birthweight
Candidiasis
Primary: Death or Candidiasis — 31; 37 participants
Phase 2 N=22 Oral Ibrexafungerp (SCY-078) vs Standard-of-Care Following IV Echinocandin in the Treatment of Invasive Candidiasis
Mycoses · Candidiasis, Invasive · Candidemia
Primary: Safety and Tolerability, Assessed by Adverse Events, Clinical Laboratory Results, Physical Examination Findings, ECG Results, and Vital Sign Measurements — 1; 1; 0; 0…
N/A N=64 β-D-Glucan (BDG) Surveillance With Preemptive Anidulafungin vs. Standard Care for Invasive Candidiasis in Surgical Intensive Care Unit (SICU) Patients
Invasive Candidiasis
Primary: Clinical Utility of Biweekly β-D-glucan (BDG) Testing in At-risk Intensive Care Unit (ICU) Patients. — 3; 3; 19; 9 participants
Phase 4 N=282 Study Will Evaluate The Safety And Efficacy Of Anidulafungin In Patients With Candidemia Or Invasive Candidiasis
Candidiasis
Primary: Number of Participants With Global Response of Success or Failure (Based on Clinical and Microbiological Response) at End of Treatment (EOT) — 170; 33 participants
Phase 2 N=4 CAMB/MAT2203 in Patients With Mucocutaneous Candidiasis
Candidiasis, Chronic Mucocutaneous
Primary: Clinical Response to Treatment of Mucocutaneous Candidiasis — 4 Participants
Phase 3 N=63 A Study of Caspofungin Acetate (MK0991) for the Treatment of Esophageal Candidiasis or Invasive Candidiasis in Chinese Adults (MK-0991-066)
Fungal Infection
Primary: Number of Participants With One or More Drug-related Serious Adverse Events — 0 Participants
Phase 2 N=21 An Efficacy and Safety Study of APX001 in Non-Neutropenic Patients With Candidemia
Candidemia
Primary: Treatment Success at End of Study Treatment (EOST) as Determined by the Data Review Committee (DRC) — 16 Participants
Phase 2 N=9 An Open-label Study of APX001 for Treatment of Patients With Candidemia/Invasive Candidiasis Caused by Candida Auris
Candidemia · Invasive Candidiases · Candida Infection
Primary: Percentage of Participants With Treatment Success at End of Study Treatment (EOST) as Determined by Data Review Committee (DRC) — 88.9 Percentage of participants
N/A N=239 Anti-mold Azole in the Prophylaxis for Invasive Fusariosis
Fusariosis · Onychomycosis
Primary: Proportion of Patients Who Develop Invasive Fusariosis Until Neutrophil Recovery — 6; 8 Participants
Phase 4 N=45 Voriconazole for Secondary Prophylaxis of Invasive Fungal Infections in Patients With Allogeneic Stem Cell Transplants
Prophylaxis Of Invasive Fungal Infections
Primary: Occurrence of Proven or Probable Invasive Fungal Infection (IFI): Start of Prophylaxis Until 12-month Follow-up Visit — 3 participants
Phase 4 N=85 Negative Beta Glucan in ICU Patients
Candidemia
Primary: Evaluate the Ocurrence of Candidemia in Patients With Negative 1,3 Beta-D-glucan Who Discontinue Anidulafungin — 0; 21 Participants
N/A N=323 Caspofungin or Micafungin as Empiric Antifungal Therapy for Persistent Fever and Neutropenia
Febrile Neutropenia
Primary: Composite Primary Endpoint: Number of Participants With an Overall Favorable Response to Echinocandin Therapy for Empiric Antifungal Therapy for Persistent Febrile…
Phase 3 N=70 Study To Assess Pharmacokinetics, Safety & Efficacy of Anidulafungin When Treating Children With Invasive Candidiasis
Candidemia
Primary: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) — 17; 19; 30; 7 Participants
Phase 3 N=43 Anidulafungin In Treatment Of Candidemia In Asian Subjects
Candidemia
Primary: Number of Subjects With Global Response of Success at End of Treatment — 31 participants
Phase 2 N=46 Caspofungin Maximum Tolerated Dose in Patients With Invasive Aspergillosis
Invasive Aspergillosis
Primary: Safety and Tolerability of Caspofungin in Four Escalating Dosages in Adult Patients With Hematologic Malignancies and Proven or Probable Invasive Aspergillosis — 11; 12…
Phase 4 N=21 Comparison of Candida Eradication and Serum Cidal Activity of Echinocandins
Candidemia
Primary: Serum Cidal Activity as Tested Against Various Candida Isolates and Reported as Ex-vivo Effect (Log Inhibition of Growth) — 3; 0.5; 0; 3 Log inhibition
N/A N=130 Assessment of the Fungal Infection Incidence Across Canada for High Risk Participants With Hematological Disease (P07501)
Mycoses · Leukemia
Primary: Percentage of Participants With Non-Candida Invasive Fungal Infections at a Single Institution — 32.3 Percentage of participants
Phase 4 N=54 This Is An Open-Label, Non-Comparative Study Designed To Evaluate A Short Course Of IV Anidulafungin, Followed Optionally By Oral Voriconazole, For The Treatment Of Candidemia And Invasive Candidiasis
Candidemia · Invasive Candidiasis
Primary: Number of Participants for Global Response (Based on Clinical and Microbiological Success or Failure) at End of Treatment — 26; 18 participants
Phase 3 N=517 Caspofungin Versus Fluconazole in Preventing Invasive Fungal Infections (IFI) in Patients Undergoing Chemotherapy for Acute Myeloid Leukemia
Acute Myeloid Leukemia · Adult Acute Monoblastic Leukemia · Adult Acute Monocytic Leukemia
Primary: Percentage of Participants With Proven or Probable Invasive Fungal Infections (IFI) — 3.1; 7.2 Percentage of participants
Phase 2 N=168 High-Dose Fluconazole for the Treatment of Cryptococcal Meningitis in HIV-Infected Individuals
Cryptococcal Meningitis · HIV Infections
Primary: Number of Participants Who Discontinued Study-provided High Dose Fluconazole or Ampho B — 14; 11; 11; 6 Participants — p=0.0012
Phase 4 N=13 Antifungal Locks to Treat Fungal-related Central Line Infections
Central Line Fungal Infections
Primary: Number of Patients With 2 Negative Fungal Cultures After 5 Days of Combined Systemic Antifungal and Antifungal Lock Therapy and the CVC Was Not Removed — 10; 3…
Phase 3 N=30 Open-Label Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) in Patients With Candidiasis Caused by Candida Auris (CARES)
Candidiasis, Invasive · Candidemia
Primary: Percentage of Participants With Global Success at End of Treatment as Determined by the Data Monitoring Committee — 21 Participants
Phase 2 N=215 A Study to Evaluate Oral VT-1161 in the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)
Recurrent Vulvovaginal Candidiasis
Primary: The Percentage of Subjects With 1 or More Culture-verified Acute VVC Episodes Through Week 48 of the Study in the Intent-to-treat Population. — 2; 3; 0; 2 Participants